Sergey Yagoda, MD

  • 4Articles
  • 43KReads
  • 2020–2024Active
  • 22Collaborators
  • 41Citations

About

Sergey Yagoda is affiliated with Alkermes, Inc, in Waltham, Massachusetts, and has published extensively between 2020 and 2024 on topics related to schizophrenia, schizoaffective disorders, psychotic disorders, and weight management. His work focuses on the safety, tolerability, and efficacy of antipsychotic treatments, including aripiprazole lauroxil and olanzapine/samidorphan regimens, particularly in acute and early illness phases. Yagoda's research often involves clinical trial analyses and comparative studies of long-acting injectable formulations in patients with psychotic disorders.

Publications

JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
, , , et al
JCP
Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months
Original Research

Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months

February 28, 2024

In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.
, , , et al
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
, , , et al
JCP
Original Research

Aripiprazole Lauroxil to Treat Schizophrenia

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe